210 related articles for article (PubMed ID: 37284308)
41. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
[TBL] [Abstract][Full Text] [Related]
42. Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
Krulikas L; Bates J; Chanfreau C; Coleman H; Dalton S; Voora D
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38775021
[TBL] [Abstract][Full Text] [Related]
43. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
45. Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.
Jameson A; Faisal M; Fylan B; Bristow GC; Sohal J; Dalton C; Sagoo GS; Cardno AG; McLean SL
J Psychopharmacol; 2024 Apr; 38(4):382-394. PubMed ID: 38494658
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis.
Lenz C; Narang A; Bousman CA
Pharmacogenet Genomics; 2024 Jun; 34(4):130-134. PubMed ID: 38359167
[TBL] [Abstract][Full Text] [Related]
47. Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.
Chhibber A; Watanabe AH; Jacobs H; Kharat A; Syeed SM; Sherwin CM; Chaiyakunapruk N; Biskupiak J; Yellepeddi VK; Brixner D; Young DC
J Cyst Fibros; 2024 Jun; ():. PubMed ID: 38937211
[TBL] [Abstract][Full Text] [Related]
48. Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.
Kennedy AM; Griffiths AM; Muise AM; Walters TD; Ricciuto A; Huynh HQ; Wine E; Jacobson K; Lawrence S; Carman N; Mack DR; deBruyn JC; Otley AR; Deslandres C; El-Matary W; Zachos M; Benchimol EI; Critch J; Schneider R; Crowley E; Li M; Warner N; McGovern DPB; Li D; Haritunians T; Rudin S; Cohn I
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38788739
[TBL] [Abstract][Full Text] [Related]
49. Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson's Disease in African and African Admixed Populations.
Rizig M; Bandres-Ciga S; Makarious MB; Ojo O; Crea PW; Abiodun O; Levine KS; Abubakar S; Achoru C; Vitale D; Adeniji O; Agabi O; Koretsky MJ; Agulanna U; Hall DA; Akinyemi R; Xie T; Ali M; Shamim EA; Ani-Osheku I; Padmanaban M; Arigbodi O; Standaert DG; Bello A; Dean M; Erameh C; Elsayed I; Farombi T; Okunoye O; Fawale M; Billingsley KJ; Imarhiagbe F; Jerez PA; Iwuozo E; Baker B; Komolafe M; Malik L; Nwani P; Daida K; Nwazor E; Miano-Burkhardt A; Nyandaiti Y; Fang ZH; Obiabo Y; Kluss JH; Odeniyi O; Hernandez D; Odiase F; Tayebi N; Ojini F; Sidranksy E; Onwuegbuzie G; D'Souza AM; Osaigbovo G; Berhe B; Osemwegie N; Reed X; Oshinaike O; Leonard H; Otubogun F; Alvarado CX; Oyakhire S; Ozomma S; Samuel S; Taiwo F; Wahab K; Zubair Y; Iwaki H; Kim JJ; Morris HR; Hardy J; Nalls M; Heilbron K; Norcliffe-Kaufmann L; ; Blauwendraat C; Houlden H; Singleton A; Okubadejo N
medRxiv; 2023 May; ():. PubMed ID: 37398408
[TBL] [Abstract][Full Text] [Related]
50. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
51. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
[TBL] [Abstract][Full Text] [Related]
52. The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK; Somogyi AA; Rubio J; Philip J
Curr Treat Options Oncol; 2022 Oct; 23(10):1353-1369. PubMed ID: 36001223
[TBL] [Abstract][Full Text] [Related]
53. Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics.
Pandi MT; Williams MS; van der Spek P; Koromina M; Patrinos GP
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32443490
[TBL] [Abstract][Full Text] [Related]
54. Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting.
Wick JA; Schmidlen T; Grande K; Moretz C; Ashcraft K; Green J; Moyer N; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(1):188-192. PubMed ID: 36243653
[TBL] [Abstract][Full Text] [Related]
55. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
56. Analytical validation of GenoPharm a clinical genotyping open array panel of 46 pharmacogenes inclusive of variants unique to people of African ancestry.
Kanji CR; Mbavha BT; Masimirembwa C; Thelingwani RS
PLoS One; 2023; 18(10):e0292131. PubMed ID: 37788265
[TBL] [Abstract][Full Text] [Related]
57. A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.
Nunez-Torres R; Pita G; Peña-Chilet M; López-López D; Zamora J; Roldán G; Herráez B; Álvarez N; Alonso MR; Dopazo J; Gonzalez-Neira A
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111771
[TBL] [Abstract][Full Text] [Related]
58. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
59. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
[No Abstract] [Full Text] [Related]
60. Clinical implementation of preemptive pharmacogenomics in psychiatry.
Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
